SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (573)9/18/2001 6:38:45 PM
From: LemurHouse  Respond to of 656
 
Thanks for posting that story.

IMNX is currently conducting a PhII study for using Enbrel to treat ankylosing spondylitis -- the malady mentioned in the article -- and is expected to report data this quarter or next, with Ph III trials expected to begin in Q1 of 2002.

Other indications being investigated are for Wegener's Granulomatosis, for which Ph II and III trials are currently underway.

A second, larger Ph II trial is being initiated for Psoriasis, following positive results from initial small Ph II.

Correction to my earlier post: psoriatic arthritis req was submitted in mid-July, not June.

AD



To: Arthur Radley who wrote (573)9/19/2001 2:04:32 PM
From: eric ross  Read Replies (1) | Respond to of 656
 
Any buy back program that you know of? or the possibility of being acquired by AHP?



To: Arthur Radley who wrote (573)9/20/2001 4:11:40 PM
From: eric ross  Read Replies (1) | Respond to of 656
 
What happened?..The rally was so good especially in this down market that I sold at 18. Hopefully, I could buy it back..


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News